Results 51 to 60 of about 12,502 (244)

Inhaled levosimendan versus intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement

Annals of Cardiac Anaesthesia, 2018
Context: Inhaled levosimendan may act as selective pulmonary vasodilator and avoid systemic side effects of intravenous levosimendan, which include decrease in systemic vascular resistance (SVR) and systemic hypotension, but with same beneficial effect ...
Tanveer Singh Kundra, P S Nagaraja, K S Bharathi, Parminder Kaur, N Manjunatha   +4 more
doaj   +1 more source

Use of levosimendan in hemodynamic management of heart failure in two neonates with intracranial arteriovenous shunts: a case series

Italian Journal of Pediatrics, 2023
Background The hemodynamic status of newborns with intracranial arteriovenous shunts (AVSs) may be extremely complex. Mini-invasive hemodynamic monitoring through innovative techniques such as Near-Infrared Spectroscopy (NIRS) and Pressure Recording ...
Francesca Landolfo, Paola Giliberti, Domenico Umberto De Rose, Flaminia Pugnaloni, Alessandra Santisi, Claudia Columbo, Ludovica Martini, Maria Paola Ronchetti, Luca Di Chiara, Alessandra Toscano, Carlo Gandolfo, Andrea Dotta, Irma Capolupo   +12 more
doaj   +1 more source

Cardiac Ischemia On-a-Chip: Antiarrhythmic Effect of Levosimendan on Ischemic Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Cells, 2022
Ischemic heart disease (IHD) is one of the leading causes of mortality worldwide. Preserving functionality and preventing arrhythmias of the heart are key principles in the management of patients with IHD.
Mahmoud Gaballah, K. Penttinen, J. Kreutzer, Antti-Juhana Mäki, P. Kallio, K. Aalto-Setälä   +5 more
semanticscholar   +1 more source

Levosimendan in intensive care and emergency medicine: literature update and expert recommendations for optimal efficacy and safety

Journal of Anesthesia Analgesia and Critical Care, 2022
The inodilator levosimendan, in clinical use for over two decades, has been the subject of extensive clinical and experimental evaluation in various clinical settings beyond its principal indication in the management of acutely decompensated chronic ...
M. Girardis, D. Bettex, M. Bojan, C. Demponeras, S. Fruhwald, J. Gal, H. Groesdonk, F. Guarracino, J. Guerrero-Orriach, M. Heringlake, A. Herpain, L. Heunks, J. Jin, D. Kindgen-Milles, P. Mauriat, G. Michels, V. Psallida, S. Rich, Sven-Erick Ricksten, A. Rudiger, M. Siegemund, W. Toller, S. Treskatsch, Ž. Župan, P. Pollesello   +24 more
semanticscholar   +1 more source

Calcium sensitizers: What have we learned over the last 25years? [PDF]

, 2018
K
Papp, Gy. Julius, Papp, Zoltán, Pollesello, Piero   +2 more
core   +1 more source

Prophylactic levosimendan in patients with low ejection fraction undergoing coronary artery bypass grafting: A pooled analysis of two multicentre randomised controlled trials.

Anaesthesia Critical Care & Pain Medicine, 2022
OBJECTIVES To assess the effect of preoperative levosimendan on mortality at Day-90 in patients with left ventricular ejection fraction (LVEF) ≤ 40%, and to investigate a possible differential effect between patients undergoing isolated coronary artery ...
T. Caruba, A. Charles-Nelson, J. Alexander, R. Mehta, M. Heringlake, W. Toller, A. Yavchitz, B. Sabatier, G. Chatellier, B. Cholley   +9 more
semanticscholar   +1 more source

European experience on the practical use of levosimendan in patients with acute heart failure syndromes [PDF]

, 2005
The novel calcium sensitizer and ATP-dependent potassium channel opener levosimendan has been introduced for routine use in several European countries. Recent reports on clinical experience confirm the positive hemodynamic results and beneficial clinical
Cardoso, JS, Follath, F, Franco, F
core   +1 more source

Levosimendán preoperatorio en cirugía coronaria con disfunción ventricular severa: ¿tiene sentido?

Cirugía Cardiovascular, 2021
Resumen: Introducción y objetivos: Numerosos estudios han demostrado los beneficios del levosimendán en pacientes con insuficiencia cardiaca crónica y aguda; sin embargo, los resultados son contradictorios cuando se analiza el uso de levosimendán previo
Elena Roselló-Díez, Eduardo Astrosa, Sandra Casellas, Manel Tauron, Josefina Galán, Antonino Ginel, José Montiel   +6 more
doaj   +1 more source

Levosimendan Increases Survival in a D-Galactosamine and Lipopolysaccharide Rat Model

Biomedicines, 2022
Levosimendan, a calcium sensitizer, has an organ protective profile through the inhibition of inflammatory mediators and cytokines in critical conditions, such as heart failure, ischemia-reperfusion injury, and sepsis. The survival effect of levosimendan
Tatsuma Sakaguchi, Fusao Sumiyama, Masaya Kotsuka, Masahiko Hatta, Terufumi Yoshida, Mikio Hayashi, Masaki Kaibori, Mitsugu Sekimoto   +7 more
doaj   +1 more source

Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. [PDF]

, 2019
Current pharmacological therapies for heart failure with reduced ejection fraction are largely either repurposed anti-hypertensives that blunt overactivation of the neurohormonal system or diuretics that decrease congestion.
Ahmad, T, Allen, LA, Böhm, M, Desai, NR, Lindenfeld, J, McCullough, M, Miller, PE, Psotka, M, Riello, R, Rosano, GMC, Teerlink, JR   +10 more
core   +2 more sources